TY  - GEN
AU  - Verstovsek,Srdan
AU  - Kantarjian,Hagop M
AU  - Estrov,Zeev
AU  - Cortes,Jorge E
AU  - Thomas,Deborah A
AU  - Kadia,Tapan
AU  - Pierce,Sherry
AU  - Jabbour,Elias
AU  - Borthakur,Gautham
AU  - Rumi,Elisa
AU  - Pungolino,Ester
AU  - Morra,Enrica
AU  - Caramazza,Domenica
AU  - Cazzola,Mario
AU  - Passamonti,Francesco
TI  - Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
SN  - 1528-0020
PY  - 2012///1025
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Case-Control Studies
KW  - Clinical Trials, Phase I as Topic
KW  - statistics & numerical data
KW  - Clinical Trials, Phase II as Topic
KW  - Clinical Trials, Phase III as Topic
KW  - Cohort Studies
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Janus Kinase 1
KW  - antagonists & inhibitors
KW  - Janus Kinase 2
KW  - Male
KW  - Middle Aged
KW  - Nitriles
KW  - Primary Myelofibrosis
KW  - diagnosis
KW  - Protein Kinase Inhibitors
KW  - therapeutic use
KW  - Pyrazoles
KW  - Pyrimidines
KW  - Randomized Controlled Trials as Topic
KW  - Survival Analysis
KW  - Survivors
KW  - Treatment Outcome
KW  - Assessment of Medication Adherence
N1  - Publication Type: Comparative Study; Evaluation Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1182/blood-2012-02-414631
ER  -